Aspire Biopharma
ASBP
28 hedge funds and large institutions have $900K invested in Aspire Biopharma in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
39% more capital invested
Capital invested by funds: $646K → $900K (+$254K)
22% more funds holding
Funds holding: 23 → 28 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$523K |
| 2 |
Jane Street
New York
|
+$137K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$49.5K |
| 4 |
VF
Virtu Financial
New York
|
+$22.8K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$20.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Procyon Advisors
Shelton,
Connecticut
|
-$50K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.5K |
| 3 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$2.58K |
| 4 |
SWA
SOA Wealth Advisors
New York
|
-$602 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$500 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
Allred Capital Management
Dallas,
Texas
| $1.48K | – | – | – |
|
27
Fisher Asset Management
Camas,
Washington
| $1.32K | +$2K | +8 | New |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $1.27K | -$4.5K | -18 | -69% |
|
29
Bank of America
Charlotte,
North Carolina
| $37 | – | – | – |
|
30
Osaic Holdings
Scottsdale,
Arizona
| $13 | – | – | – |
|
|
31
Focus Partners Wealth
Boston,
Massachusetts
| – | -$2.58K | -10 | Closed |
|
|
SWA
32
SOA Wealth Advisors
New York
| – | -$602 | -2 | Closed |
|
ASBP Hedge Fund Activity: Q4 2025 in Review
28 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2025, worth a combined $900K — up 39% from $646K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ASBP positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, adding an estimated $523K. The largest seller was Procyon Advisors, cutting an estimated $50K.
- 28 institutional investors held Aspire Biopharma (ASBP) as of Q4 2025, up from 23 in Q3 2025.
- Funds reported $900K of Aspire Biopharma stock for Q4 2025, up 39% quarter-over-quarter.
- 7 funds opened new Aspire Biopharma positions in Q4 2025 and 2 closed out, a net change of +5 holders.
- The largest Aspire Biopharma buyer in Q4 2025 was UBS Group, an estimated $523K added.
- The largest Aspire Biopharma seller in Q4 2025 was Procyon Advisors, an estimated $50K sold.
Based on aggregated 13F filings for Q4 2025.